A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to
a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in
repeated doses (4 injections) administered in the deltoid muscle (muscle in the shoulder) or
gluteal muscle (group of muscles present in the buttocks) in participants with schizophrenia.